GlycoMimetics, Inc. announced that its stockholders have approved a proposed merger with Crescent Biopharma, Inc., along with all related proposals. At a special meeting held on June 5, 2025, stockholders also approved a 1-for-100 reverse stock split, which will reduce the number of outstanding common stock from approximately 64.5 million shares to about 0.6 million shares. Following the anticipated closing of the merger, the combined company's stock will trade under the new name "Crescent Biopharma, Inc." with the ticker symbol "CBIO" on Nasdaq, beginning June 16, 2025. The total issued and outstanding common stock of the combined company is expected to be approximately 14.8 million shares, or roughly 25.3 million shares on a fully-diluted basis.